Journal of International Oncology››2019,Vol. 46››Issue (1): 6-10.doi:10.3760/cma.j.issn.1673-422X.2019.01.002
Previous ArticlesNext Articles
Chen Yiming, Zhou Yi
Received:
2018-09-29Online:
2019-01-08Published:
2019-04-03Contact:
Zhou Yi E-mail:lubj2001@163.cmChen Yiming, Zhou Yi. Expressions of PTEN and E-cadherin in breast cancer tissues and their clinical significance[J]. Journal of International Oncology, 2019, 46(1): 6-10.
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492. [2] Zhang Z, Sun L, Zhang Y, et al. Long noncoding RNA FEZF1AS1 promotes breast cancer stemness and tumorigenesis via targeting miR30a/Nanog axis[J]. J Cell Physiol, 2018, 233(11): 8630-8638. DOI: 10.1002/jcp.26611. [3] Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta[J]. Cancer Res, 1997, 57(11): 2124-2129. [4] Wong SHM, Fang CM, Chuah LH, et al. Ecadherin: its dysregulation in carcinogenesis and clinical implications[J]. Crit Rev Oncol Hematol, 2018, 121: 11-22. DOI: 10.1016/j.critrevonc.2017.11.010. [5] Chen CY, Chen J, He L, et al. PTEN: tumor suppressor and metabolic regulator[J]. Front Endocrinol (Lausanne), 2018, 9: 338. DOI: 10.3389/fendo.2018.00338. [6] Kechagioglou P, Papi RM, Provatopoulou X, et al. Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression[J]. Anticancer Res, 2014, 34(3): 1387-1400. [7] Wang LL, Hao S, Zhang S, et al. PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases[J]. Hum Pathol, 2017, 61: 49-57. DOI: 10.1016/j.humpath.2016.07.040. [8] Li S, Shen Y, Wang M, et al. Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis[J]. Oncotarget, 2017, 8(19): 3204332054. DOI: 10.18632/oncotarget.16761. [9] GschwantlerKaulich D, Tan YY, Fuchs EM, et al. PTEN expression as a predictor for the response to trastuzumabbased therapy in Her-2 overexpressing metastatic breast cancer[J]. PLoS One, 2017, 12(3): e0172911. DOI: 10.1371/journal.pone.0172911. [10] Mendonsa AM, Na TY, Gumbiner BM. Ecadherin in contact inhibition and cancer[J]. Oncogene, 2018, 37(35): 4769-4780. DOI: 10.1038/s41388-018-0304-2. [11] Li Z, Yin S, Zhang L, et al. Prognostic value of reduced Ecadherin expression in breast cancer: a metaanalysis[J]. Oncotarget, 2017, 8(10): 16445-16455. DOI: 10.18632/oncotarget.14860. [12] 谢莉莉, 王东林. 乳腺癌患者HER-2、PCNA和E-cadherin蛋白表达及临床病理特征与预后的相关性[J]. 现代肿瘤医学, 2017, 25(18): 2929-2934. DOI: 10.3969/j.issn.1672-4992.2017.18.019. [13] 谭敏华, 雷伟华, 谭冬玲, 等. 浸润性乳腺癌ER、PR、HER2、Ecadherin、CK5/6检测与临床预后关系[J]. 临床与实验病理学杂志, 2011, 27(9): 933938. DOI: 10.3969/j.issn.10017399.2011.09.004. [14] Memni H, Macherki Y, Klayech Z, et al. Ecadherin genetic variants predict survival outcome in breast cancer patients[J]. J Transl Med, 2016, 14(1): 320. DOI: 10.1186/s12967-016-1077-4. [15] Li Z, Wang L, Zhang W, et al. Restoring Ecadherinmediated cellcell adhesion increases PTEN protein level and stability in human breast carcinoma cells[J]. Biochem Biophys Res Commun, 2007, 363(1): 165-170. DOI: 10.1016/j.bbrc.2007.08.154. [16] Asproni P, Ressel L, Millanta F, et al. Colocalization of PTEN and Ecadherin in canine mammary hyperplasias and benign and malignant mammary tumors[J]. Res Vet Sci, 2015, 103: 113-118. DOI: 10.1016/j.rvsc.2015.09.022. |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[4] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[5] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[6] | Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197. |
[7] | Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209. |
[8] | Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222. |
[9] | Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234. |
[10] | Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238. |
[11] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[12] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[13] | Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185. |
[14] | Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[15] | Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||